Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis
作者:Jérémie Piton、Anthony Vocat、Andréanne Lupien、Caroline S. Foo、Olga Riabova、Vadim Makarov、Stewart T. Cole
DOI:10.1128/aac.00681-18
日期:2018.10
tuberculosis As part of the MCZ backup program, we exploited structure-guided drug design to produce a new series of sulfone-containing derivatives, 2-sulfonylpiperazin 8-nitro 6-trifluoromethyl 1,3-benzothiazin-4-one, or sPBTZ. These compounds are less active than MCZ but have a better solubility profile, and some derivatives display enhanced stability in microsomal assays. DprE1 was efficiently inhibited by
Macozinone(MCZ)是一种结核病(TB)候选药物,它专门针对必需的黄素酶DprE1,从而阻止细胞壁前体癸二烯基磷酸阿拉伯糖(DPA)的合成并引起结核分枝杆菌的裂解。作为MCZ备用计划的一部分,我们利用了结构-指导药物设计,以生产一系列新的含砜衍生物,即2-磺酰基哌嗪8-硝基6-三氟甲基1,3-苯并噻嗪-4-酮或sPBTZ。这些化合物的活性不如MCZ,但具有更好的溶解度,某些衍生物在微粒体测定中显示出更高的稳定性。sPBTZ有效抑制了DprE1,并与活性位点的半胱氨酸残基(C387)形成了共价加合物。但是,尽管砜基具有氢键键合潜力,与MCZ相比,在具有化合物11326127的sPBTZ-DprE1配合物的晶体结构中未发现其他键。化合物11626091(最先进的sPBTZ)在慢性结核病的鼠模型中显示出良好的抗结核活性,但效果不如MCZ。尽管如此,仍需对该MCZ备用化合物进行进一步